Poly

Open PR | December 28, 2016

Although, the use of PCR has been mostly confined to research institutions, pharmaceutical and biotechnology industries, currently, the market has seen an increasing preference of PCR in the commercial diagnostic laboratories and hospitals due to precise diagnoses of life-threatening diseases such as cancer and Ebola. Multi-chain diagnostic laboratories are currently focusing on expanding their operations in less developed areas by acquiring standalone laboratories with minimal infrastructure. T...

The Economic Times | January 27, 2017

Doctors and aid organisations have called upon the Competition Commission of India and the price regulator to step in to ward off the monopoly over a new HIV drug, dolutegravir, which received the approval of the Indian drug controller last month....

fiercepharma | May 09, 2018

Gilead Sciences is no stranger to furious patients and advocates, many of whom have said over the years that the company puts shareholder interests over their own. Now, two patients allege that the drugmaker shelved better HIV treatments in favor of monopoly sales and at the detriment of their health. Gilead's Viread, or tenofovir disoproxil fumarate (TDF), won FDA approval in 2001. The plaintiffs, California residents Michael Lujano and Jonathan Gary, allege that the company knew the compou...

Phys.org | October 09, 2018

Recipes for three-dimensional (3-D) printing, or additive manufacturing, of parts, have required as much guesswork as science. Until now. Resins and other materials that react under light to form polymers, or long chains of molecules, are attractive for 3-D printing of parts ranging from architectural models to functioning human organs. But it's been a mystery what happens to the materials' mechanical and flow properties during the curing process at the scale of a single voxel. A voxel i...